Community Webinar: Management and Access to Care for Female Carriers of Duchenne

Dr. Markham’s clinical interests and investigations have been focused in congenital heart conditions and inherited conditions with cardiovascular phenotype. One particular area of focus has been predictors of Duchenne Muscular Dystrophy cardiomyopathy disease progression to heart failure and death. Dr. Markham served as a member of the CDC Care Considerations Working Group, co-chair of the PPMD and NHLBI-sponsored Working Group on Contemporary Cardiac Issues in Duchenne Muscular Dystrophy and co-author of the 2017 AHA Scientific Statement entitled “Management of Cardiac Involvement Associated With Neuromuscular Diseases.”

Dr. Markham is Co-PI for the recently funded R01 entitled “Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials” [1R01HL167969 (PI: Soslow/Markham/Goergen/Hor/Lin)]. As the Division Chief for Pediatric Cardiology and Co-Director of the Heart Center, he has worked to integrate cutting edge clinical care and to link translational research with patient centered outcomes across all areas of the Heart Center.